MA31867B1 - Agonistes nouveaux des recepteurs de glucocorticoides - Google Patents

Agonistes nouveaux des recepteurs de glucocorticoides

Info

Publication number
MA31867B1
MA31867B1 MA32873A MA32873A MA31867B1 MA 31867 B1 MA31867 B1 MA 31867B1 MA 32873 A MA32873 A MA 32873A MA 32873 A MA32873 A MA 32873A MA 31867 B1 MA31867 B1 MA 31867B1
Authority
MA
Morocco
Prior art keywords
glucocorticoid receptors
disorders
new agonist
new
agonist
Prior art date
Application number
MA32873A
Other languages
Arabic (ar)
English (en)
Inventor
Paul Alan Glossop
David Simon Millan
David Anthony Price
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31867(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA31867B1 publication Critical patent/MA31867B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX AGONISTES DES RÉCEPTEURS DES GLUCOCORTICOÏDES DE FORMULE (I) ET DES PROCÉDÉS ET DES INTERMÉDIAIRES POUR LEUR PRÉPARATION. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS, LEUR COMBINAISON AVEC UN OU PLUSIEURS AUTRES AGENTS THÉRAPEUTIQUES AINSI QUE LEUR UTILISATION POUR LE TRAITEMENT D'UN CERTAIN NOMBRE DE MALADIES, TROUBLES ET AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES.
MA32873A 2007-11-30 2010-05-28 Agonistes nouveaux des recepteurs de glucocorticoides MA31867B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99135407P 2007-11-30 2007-11-30
US5724108P 2008-05-30 2008-05-30
US7955508P 2008-07-10 2008-07-10
PCT/IB2008/054801 WO2009069032A2 (fr) 2007-11-30 2008-11-17 Nouveaux agonistes des récepteurs des glucocorticoïdes

Publications (1)

Publication Number Publication Date
MA31867B1 true MA31867B1 (fr) 2010-11-01

Family

ID=40427125

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32873A MA31867B1 (fr) 2007-11-30 2010-05-28 Agonistes nouveaux des recepteurs de glucocorticoides

Country Status (32)

Country Link
US (2) US8822439B2 (fr)
EP (1) EP2225256B1 (fr)
JP (1) JP4686650B2 (fr)
KR (1) KR101295998B1 (fr)
CN (1) CN101878221B (fr)
AP (1) AP2010005267A0 (fr)
AR (1) AR069490A1 (fr)
AU (1) AU2008331187B2 (fr)
BR (1) BRPI0820447A2 (fr)
CA (1) CA2706180C (fr)
CL (1) CL2008003549A1 (fr)
CO (1) CO6280401A2 (fr)
CR (1) CR11393A (fr)
DK (1) DK2225256T3 (fr)
DO (1) DOP2010000161A (fr)
EA (1) EA201070535A1 (fr)
EC (1) ECSP10010209A (fr)
ES (1) ES2399945T3 (fr)
GT (1) GT201000153A (fr)
IL (1) IL205356A0 (fr)
MA (1) MA31867B1 (fr)
MX (1) MX2010005861A (fr)
NI (1) NI201000090A (fr)
NZ (1) NZ585434A (fr)
PA (1) PA8805801A1 (fr)
PE (1) PE20091072A1 (fr)
SV (1) SV2010003580A (fr)
TN (1) TN2010000230A1 (fr)
TW (1) TW200930378A (fr)
UY (1) UY31496A1 (fr)
WO (1) WO2009069032A2 (fr)
ZA (1) ZA201003439B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087946A1 (fr) * 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Essai de criblage utilisant dex et gdf8
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
CN103380142A (zh) * 2011-03-15 2013-10-30 奇斯药制品公司 异噁唑烷衍生物
TWI658047B (zh) * 2011-03-15 2019-05-01 吉斯藥品公司 異唑啶衍生物
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
WO2014144512A1 (fr) * 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Forme pharmaceutique à dispersion rapide contenant du lévétiracétam
EP3244893A4 (fr) 2015-02-18 2019-01-09 Parion Sciences, Inc. Bloqueurs de canaux sodiques pour le traitement de troubles de la peau
WO2017189805A1 (fr) 2016-04-27 2017-11-02 Abbvie Inc. Méthodes de traitement de maladies dans lesquelles l'activité de l'il-13 est préjudiciable à l'aide d'anticorps anti-il-13
RS62040B1 (sr) * 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
RU2020117156A (ru) * 2017-12-01 2022-01-04 Эббви Инк. Конъюгаты анти-cd40 антитела и лекарственного средства
EP3658192B1 (fr) * 2017-12-01 2021-04-28 AbbVie Inc. Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
WO2019180150A1 (fr) 2018-03-22 2019-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de modulation de l'activité des cellules lymphoïdes innées, conjugués anticorps-médicaments et leurs utilisations en thérapie
CN109651474A (zh) * 2019-01-20 2019-04-19 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙的新的制备方法
CN109575095A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙的制备方法
CN109734763A (zh) * 2019-01-20 2019-05-10 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙产品的制备方法
CN109575097A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙产品的新的制备方法
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
CN117043172A (zh) * 2021-03-23 2023-11-10 伊莱利利公司 糖皮质激素受体激动剂
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
EP4365183A4 (fr) * 2021-06-24 2025-12-03 Jiangsu Simcere Pharm Co Ltd Composé stéroïde, composition pharmaceutique et utilisation associées
JP2024531480A (ja) * 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
WO2023245106A1 (fr) 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Conjugués médicament-anticorps anti-cd19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
EP1567113A4 (fr) 2002-10-24 2006-11-08 G & R Pharmaceuticals Llc Preparations antifongiques
WO2005044759A2 (fr) * 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalisation pour preparation de composes steroides
WO2005028495A1 (fr) * 2003-09-24 2005-03-31 Glaxo Group Limited Glucocorticoïdes anti-inflammatoires
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US20050227927A1 (en) 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis

Also Published As

Publication number Publication date
CA2706180C (fr) 2012-10-23
WO2009069032A2 (fr) 2009-06-04
TW200930378A (en) 2009-07-16
AU2008331187B2 (en) 2014-04-03
KR20100074306A (ko) 2010-07-01
GT201000153A (es) 2012-04-27
EA201070535A1 (ru) 2010-12-30
SV2010003580A (es) 2011-03-23
EP2225256B1 (fr) 2013-01-09
IL205356A0 (en) 2010-12-30
PA8805801A1 (es) 2009-07-23
AR069490A1 (es) 2010-01-27
AU2008331187A1 (en) 2009-06-04
CA2706180A1 (fr) 2009-06-04
ZA201003439B (en) 2011-02-23
TN2010000230A1 (fr) 2011-11-11
CO6280401A2 (es) 2011-05-20
NI201000090A (es) 2010-10-04
ES2399945T3 (es) 2013-04-04
AP2010005267A0 (en) 2010-06-30
ECSP10010209A (es) 2010-06-29
MX2010005861A (es) 2010-06-11
CL2008003549A1 (es) 2009-11-20
HK1144821A1 (en) 2011-03-11
UY31496A1 (es) 2009-07-17
US20140336160A1 (en) 2014-11-13
WO2009069032A3 (fr) 2009-08-06
JP4686650B2 (ja) 2011-05-25
CR11393A (es) 2010-05-19
US20090227548A1 (en) 2009-09-10
NZ585434A (en) 2012-06-29
US8822439B2 (en) 2014-09-02
CN101878221A (zh) 2010-11-03
DOP2010000161A (es) 2010-07-15
DK2225256T3 (da) 2013-03-11
KR101295998B1 (ko) 2013-08-13
PE20091072A1 (es) 2009-07-23
BRPI0820447A2 (pt) 2015-05-26
CN101878221B (zh) 2014-04-02
EP2225256A2 (fr) 2010-09-08
JP2011505350A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA32798B1 (fr) Acides naphtylacétiques
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA30999B1 (fr) Composés.
MA35576B1 (fr) Nouveaux composés
TN2009000028A1 (fr) Agonistes de ep2
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation